Abstract
Background Cancers of the digestive tract, notably colorectal cancer (CRC) and pancreatic malignancies, represent a major global health burden, with microbial risk factors remaining poorly understood. Atovaquone-proguanil (A-P), an antimalarial agent, has been associated with reduced CRC incidence. We hypothesized that A-P may lower the risk of digestive cancers by eliminating Toxoplasma gondii, a protozoan capable of colonizing the digestive mucosa.
Methods Using the TriNetX US Collaborative Network, we conducted propensity score-matched cohort analyses of patients aged 40-49 (mean age, 45.2 years), 50-59 (mean, 54.8), and 60-69 (mean, 64.6) who had received A-P versus any other medication. We assessed incident digestive cancers and calculated hazard ratios (HRs). Independently, we reanalyzed metagenomic data from 1,044 fecal microbiota samples (PRJEB6070; 156 individuals), quantifying T. gondii sequence reads among 8,425 microbial species and evaluating associations with CRC using the Mann-Whitney U test.
Results A-P use was associated with a 49-54% lower risk of digestive cancers, with HRs of 0.51, 0.46, and 0.46 across the three age groups, respectively (P<0.0001). Protective associations extended to pancreatic malignancies (HRs, 0.55, 0.71, and 0.69; P<0.05). The reduced risk persisted more than a decade after treatment. In metagenomic analyses, T. gondii most strongly differentiated CRC from non-cancer samples (P=1.8×10-16); its presence (≥50 reads) was associated with an odds ratio of 18.2 for CRC (P=2.3×10-22).
Conclusions T. gondii may represent a major, underrecognized microbial risk factor for digestive cancers. The long-term protective association with A-P use may reflect eradication of this parasite, suggesting a novel target for cancer prevention.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was internally funded by Leumit Research Institute.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the statutory Leumit Health Services Institutional Review Board (approval number LEU-0010-21). Informed consent was waived because this large-scale retrospective study was performed on deidentified electronic health records.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
TriNetX epidemiologic data are accessible via the TriNetX consortium. Metagenomic sequencing data are accessible in the European Nucleotide Archive under accession number PRJEB6070."
Abbreviations
- A-P
- Atovaquone-Proguanil
- BMI
- Body mass Index
- CI
- Confidence Interval
- CRC
- colorectal cancer
- DM
- Diabetes Mellitus
- FOBT
- Fecal occult blood test
- HR
- Hazards ratio
- SMD
- Standardized Mean Difference
